Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday

Coya Therapeutics (NASDAQ:COYA) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Coya Therapeutics to post earnings of ($0.39) per share and revenue of $0.15 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The firm had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. On average, analysts expect Coya Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Coya Therapeutics Stock Down 1.4%

Shares of COYA stock traded down $0.06 during trading hours on Tuesday, reaching $4.20. 118,426 shares of the stock traded hands, compared to its average volume of 185,052. Coya Therapeutics has a 1-year low of $3.71 and a 1-year high of $7.75. The business has a fifty day moving average price of $4.45 and a 200 day moving average price of $5.17. The firm has a market capitalization of $98.53 million, a PE ratio of -3.31 and a beta of 0.55.

Analyst Ratings Changes

COYA has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research report on Friday, April 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in Coya Therapeutics in the 3rd quarter worth approximately $28,000. CIBC Private Wealth Group LLC bought a new position in Coya Therapeutics in the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP acquired a new stake in Coya Therapeutics in the 4th quarter worth $66,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Coya Therapeutics in the 2nd quarter worth $119,000. Finally, Millennium Management LLC acquired a new stake in Coya Therapeutics in the 4th quarter worth $121,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.